Osteopathic Manipulative Treatment and Postural Control: Systems Engineering Approach

October 20, 2026 updated by: Jacek Cholewicki, Michigan State University

The overall goal of this project is to develop sensitive and objective clinical research tools for the assessment of postural control of the trunk. In order to accomplish this goal, we aim to quantify balance performance in an unstable seated task. Specifically, the investigators will quantify balance performance in low back pain participants before and after osteopathic manipulative treatment. The investigators hypothesize that there will be a significant improvement in balance performance after a single session of osteopathic manipulative treatment as well as after 4 sessions of osteopathic manipulative treatment and this improvement will be greater than any learning effect.

A secondary objective of this study is to quantify differences in patient-oriented outcome measures (e.g., self-reported pain, disability) in low back pain participants before and after osteopathic manipulative treatment. The investigators hypothesize that there will be a significant improvement in these self-reported outcomes following osteopathic manipulative treatment. The association between improvement in postural control parameters and patient-oriented measures will also be explored.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

95

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Michigan
      • East Lansing, Michigan, United States, 48823
        • MSU Osteopathic Manipulative Medicine
      • Lansing, Michigan, United States, 48891
        • MSU Musculoskeletal Rehabilitation
      • Lansing, Michigan, United States, 48910
        • Michigan State University Center for Orthopedic Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

All participants must meet all of the inclusion criteria to participate in the study. Below is a list of inclusion criteria for LBP participants:

  • Age 21-65 years
  • Independently ambulatory
  • Able to speak and read English
  • Able to understand study procedures and to comply with them for the entire length of the study.
  • Willing to be randomized to either immediate or delayed treatment group.
  • Musculoskeletal pain - primarily in the low back region
  • Pain rating equal to or greater than 3 out of10 as indicated on the Numeric Rating Scale for Pain
  • Disability equal to or greater than 26% as indicated on the Oswestry Disability Questionnaire

Exclusion Criteria:

All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation. Exclusion criteria will be self-reported. However, during each treatment session, the physicians will be watching for clinical signs and symptoms not consistent with physical findings that are suggestive of the presence of any of the exclusion criteria. In such a case, further treatment will be discontinued and the subject will be excluded.

Below is a list of exclusion criteria:

  • Inability or unwillingness of individual to give written informed consent.
  • Physical therapy or any other form of manual medicine (e.g., Osteopathic Manipulative Medicine, Chiropractic Manipulation, etc.), acupuncture or spinal injections within one month prior to study enrollment
  • Workers' compensation benefits in the past 3 months or ongoing medical legal issues
  • Possibly pregnant
  • Obesity (BMI>32)
  • Currently using electrical implants (e.g., cardiac pacemakers, drug delivery pumps, etc.)

History of:

  • Spinal surgery
  • Spinal fracture
  • Spinal infection (e.g., osteomyelitis)
  • Cancer

Unresolved symptoms from:

  • Head trauma
  • Inner ear infection with associated balance and coordination problems
  • Orthostatic hypotension
  • Uncontrolled hypertension
  • Vestibular disorder (e.g. vertigo)

Current diagnosis of:

  • Significant spinal deformity (e.g., scoliosis > 20 degrees, torticollis)
  • Ankylosing spondylitis
  • Spondylolisthesis grades III or IV
  • Cauda equine syndrome
  • Rheumatoid arthritis
  • Osteoporosis
  • Angina or congestive heart failure symptoms
  • Active bleeding or infection in the back
  • Blindness
  • Seizures
  • Neurologic disease (e.g., Parkinson's disease, multiple sclerosis, cerebral palsy, Alzheimer's disease, amyotrophic lateral sclerosis, stroke or transient ischemic attack in the past year, cervical dystonia)

Conditions recognized by a physician any time during the study:

  • Significant or worsening signs of neurologic deficit
  • Symptoms are not consistent with mechanical findings
  • Other conditions impeding protocol implementation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: OMT first, then No intervention

This arm received osteopathic manipulative treatment (OMT) for approximately 4 weeks (once per week), then received no intervention after for approximately 4 weeks.

Up to 4 sessions of osteopathic manipulative treatment (once per week)

No interventions for approximately 4 weeks

Experimental: No intervention, then OMT

This arm received no intervention after for approximately 4 weeks, then received osteopathic manipulative treatment (OMT) for approximately 4 weeks (once per week).

Up to 4 sessions of osteopathic manipulative treatment (once per week)

No interventions for approximately 4 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postural Control
Time Frame: Baseline, Week 1, Week 4 (crossover), & Week 8

Postural control will be assessed in an unstable seated task, in which subjects will be asked to balance on a specially designed seat that wobbles side to side. Participant will be asked to maintain their upright posture while keeping their eyes open. The root mean square error (difference between the trunk angle from their upright position) is computed then converted to Z-score based the study populations' baseline mean and standard deviation. The score ranged from -1.67 to 2.95. Z-score of 0 indicates study population's average at the baseline. Higher Z-score indicates worse performance.

Baseline, Week 1, Week 4 (crossover), & Week 8
Trunk Muscle Reflex Latency
Time Frame: Baseline, Week 1, Week 4 (crossover), & Week 8

Subjects will be pulling with their trunk on a cable held by an electromagnet. The electromagnet will be suddenly released. Trunk muscle response to sudden load release will be measured on electromyographical recordings.

Baseline, Week 1, Week 4 (crossover), & Week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Reported Outcomes Measurement Information System (PROMIS)
Time Frame: Baseline and Week 4 (crossover point)

Assesses changes in physical function, anxiety, depression, fatigue, sleep, satisfaction with social role, and pain with Patient Reported Outcomes Measurement Information System (PROMIS) 29 questionnaire. Patients rated the statements in each domain from 0-5. Scores are summed for each domain (ranges from 4 to 20), and converted to T-scores using PROMIS conversion table (for details see http://www.healthmeasures.net/promis-scoring-manuals) . T-score of 50 indicates population average with a standard deviation of 10. Higher scores indicate worse outcomes for pain interference, sleep disturbance, fatigue, depression, and anxiety; whereas higher scores indicate better outcomes for physical function and Satisfaction with participation in social roles.

Baseline and Week 4 (crossover point)
Concomitant Medication
Time Frame: Baseline, Week 4 (crossover), Week8

Assesses the use of medication with a questionnaire. Patients were asked to report medications used within the past 7 days.

Baseline, Week 4 (crossover), Week8
Oswestry Disability Index
Time Frame: Baseline, Week 4 (crossover), and Week 8

Assesses changes in functional activities related to low back disability with the Oswestry Disability Index questionnaire. Patients selected statements that best described their condition from 10 domains affecting daily life. Each domain is scored from 0 (no disability) to 5 (highest disability). Scores from each domains are summed then percentages are calculated out of 50. Higher percentage is associated with higher disability.

Baseline, Week 4 (crossover), and Week 8
Fear Avoidance Beliefs Questionnaire
Time Frame: Baseline, Week 4 (crossover), and Week 8

The Fear Avoidance Beliefs questionnaire (FABQ) assesses effects of fear-avoidance beliefs about physical activity and work. Patients rated statements on a scale from 0 (completely disagree) to 6 (completely agree). Scores are then summed for each category: "Physical activity" (total of 4 statements, ranges from 0 to 24), and "Work" (total of 7 statements ranges from 0 to 42). Higher scores indicate stronger fear-avoidance belief (i.e. worse outcome).

Baseline, Week 4 (crossover), and Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Jacek Cholewicki, PhD, Michigan State University
  • Principal Investigator: Norman P Reeves, PhD, Michigan State University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 5, 2015

Primary Completion (Actual)

August 31, 2018

Study Completion (Actual)

August 31, 2018

Study Registration Dates

First Submitted

September 19, 2014

First Submitted That Met QC Criteria

October 9, 2014

First Posted (Estimated)

October 10, 2014

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

October 20, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • NCCAM U19 AT006057 Project 1
  • 5U19AT006057-02 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.